Digestive Diseases and Sciences

, Volume 55, Issue 12, pp 3393–3398 | Cite as

Management of Recurrence of Symptoms of Gastroesophageal Reflux Disease: Synergistic Effect of Rebamipide with 15 mg Lansoprazole

  • Norimasa Yoshida
  • Kazuhiro Kamada
  • Naoya Tomatsuri
  • Takahiro Suzuki
  • Tomohisa Takagi
  • Hiroshi Ichikawa
  • Toshikazu Yoshikawa
Original Article



Proton pump inhibitors (PPIs) are effective in healing reflux esophagitis and relieving the symptoms of gastroesophageal reflux disease (GERD). Prevention of recurrence of symptoms has become a therapeutic aim in patients with these conditions.


We investigated the effects of rebamipide, a mucosal protective anti-ulcer agent, on recurrence of reflux symptoms during PPI maintenance therapy.


Patients with esophagitis of Los Angeles classification A or B were treated with PPIs for 8 weeks. Patients with relief of symptoms were enrolled for further study. Forty-one patients were randomized to maintenance therapy with 15 mg of lansoprazole daily or 15 mg of lansoprazole and 300 mg rebamipide daily, and recurrence of symptoms was monitored over 12 months. In some patients, concentration of rebamipide and interleukin(IL)-8 expression in the esophageal mucosa were estimated.


During the 12-month period, 11/20 patients (52.4%) taking lansoprazole 15 mg daily suffered recurrence of symptoms, compared to 4/20 patients (20%) treated with lansoprazole 15 mg and rebamipide 300 mg daily (P < 0.05). Rebamipide was detected in the esophageal mucosa 90–180 min after oral administration. IL-8 mRNA expression in the esophageal mucosa of patients with rebamipide was significantly decreased compared with that of patients without rebamipide.


Combination therapy with rebamipide and lansoprazole appears to be highly effective in preventing recurrence of symptoms during long-term maintenance treatment for GERD.


Gastroesophageal reflux disease Lansoprazole Rebamipide Maintenance therapy Recurrence of symptoms Interleukin-8 


  1. 1.
    Dean BB, Gano AD Jr, Knight K, Ofman JJ, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2004;2:656–664.CrossRefPubMedGoogle Scholar
  2. 2.
    Tytgat GN. Review article: treatment of mild and severe cases of GERD. Aliment Pharmacol Ther. 2002;16(Suppl 4):73–78.CrossRefPubMedGoogle Scholar
  3. 3.
    Matheson AJ, Jarvis B. Lansoprazole: an update of its place in the management of acid-related disorders. Drugs. 2001;61:1801–1833.CrossRefPubMedGoogle Scholar
  4. 4.
    Freston JW, Jackson RL, Huang B, Ballard ED II. Lansoprazole for maintenance of remission of erosive oesophagitis. Drugs. 2002;62:1173–1184.CrossRefPubMedGoogle Scholar
  5. 5.
    Hatlebakk JG, Berstad A. Lansoprazole 15 and 30 mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis. Aliment Pharmacol Ther. 1997;11:365–372.CrossRefPubMedGoogle Scholar
  6. 6.
    Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112:1798–1810.CrossRefPubMedGoogle Scholar
  7. 7.
    Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med. 1995;333:1106–1110.CrossRefPubMedGoogle Scholar
  8. 8.
    Arakawa T, Higuchi K, Fujiwara Y, et al. 15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications. Dig Dis Sci. 2005;50:S3–S11.CrossRefPubMedGoogle Scholar
  9. 9.
    Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A. Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci. 1998;43:5S–13S.PubMedGoogle Scholar
  10. 10.
    Kleine A, Kluge S, Peskar BM. Stimulation of prostaglandin biosynthesis mediates gastroprotective effect of rebamipide in rats. Dig Dis Sci. 1993;38:1441–1449.CrossRefPubMedGoogle Scholar
  11. 11.
    Sun WH, Tsuji S, Tsujii M, et al. Induction of cyclooxygenase-2 in rat gastric mucosa by rebamipide, a mucoprotective agent. J Pharmacol Exp Ther. 2000;295:447–452.PubMedGoogle Scholar
  12. 12.
    Suetsugu H, Ishihara S, Moriyama N, et al. Effect of rebamipide on prostaglandin EP4 receptor gene expression in rat gastric mucosa. J Lab Clin Med. 2000;136:50–57.CrossRefPubMedGoogle Scholar
  13. 13.
    Tarnawski A, Arakawa T, Kobayashi K. Rebamipide treatment activates epidermal growth factor and its receptor expression in normal and ulcerated gastric mucosa in rats: one mechanism for its ulcer healing action? Dig Dis Sci. 1998;43:90S–98S.CrossRefPubMedGoogle Scholar
  14. 14.
    Tarnawski AS, Chai J, Pai R, Chiou SK. Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action? Dig Dis Sci. 2004;49:202–209.CrossRefPubMedGoogle Scholar
  15. 15.
    Udagawa A, Shiota G, Ichiba M, Murawaki Y. Effect of rebamipide on acetic acid-induced gastric ulcer in rats: involvement of hepatocyte growth factor. Scand J Gastroenterol. 2003;38:141–146.CrossRefPubMedGoogle Scholar
  16. 16.
    Ishihara K, Komuro Y, Nishiyama N, Yamasaki K, Hotta K. Effect of rebamipide on mucus secretion by endogenous prostaglandin-independent mechanism in rat gastric mucosa. Arzneimittelforschung. 1992;42:1462–1466.PubMedGoogle Scholar
  17. 17.
    Naito Y, Yoshikawa T, Tanigawa T. Hydroxyl radicals scavenging by rebamipide and related compounds: electron paramagnetic resonance study. Free Radical Biol Med. 1995;18:117–123.CrossRefGoogle Scholar
  18. 18.
    Sakurai K, Sasabe H, Koga T, Konishi T. Mechanism of hydroxyl radical scavenging by rebamipide: identification of mono-hydroxylated rebamipide as a major reaction product. Free Radic Res. 2004;38:487–494.CrossRefPubMedGoogle Scholar
  19. 19.
    Yoshikawa T, Naito Y, Tanigawa T, Kondo M. Free radical scavenging activity of the novel anti-ulcer agent rebamipide studied by electron spin resonance. Arzneimittelforschung. 1993;43:363–366.PubMedGoogle Scholar
  20. 20.
    Yoshida N, Yoshikawa T, Iinuma S, et al. Rebamipide protects against activation of neutrophils by Helicobacter pylori. Dig Dis Sci. 1996;41:1139–1144.CrossRefPubMedGoogle Scholar
  21. 21.
    Murakami K, Okajima K, Harada N, Isobe H, Okabe H. Rebamipide prevents indomethacin-induced gastric mucosal lesion formation by inhibiting activation of neutrophils in rats. Dig Dis Sci. 1998;43:139S–142S.PubMedGoogle Scholar
  22. 22.
    Masamune A, Yoshida M, Sakai Y, Shimosegawa T. Rebamipide inhibits ceramide-induced interleukin-8 production in Kato III human gastric cancer cells. J Pharmacol Exp Ther. 2001;298:485–492.PubMedGoogle Scholar
  23. 23.
    Aihara M, Imagawa K, Funakoshi Y, Ohmoto Y, Kikuchi M. Effects of rebamipide on production of several cytokines by human peripheral blood mononuclear cells. Dig Dis Sci. 1998;43:160S–166S.PubMedGoogle Scholar
  24. 24.
    Yoshida N, Uchiyama K, Kuroda M, et al. Interleukin-8 expression in the esophageal mucosa of patients with gastroesophageal reflux disease. Scand J Gastroenterol. 2004;39:816–822.CrossRefPubMedGoogle Scholar
  25. 25.
    Katada K, Yoshida N, Isozaki Y, et al. Prevention by rebamipide of acute reflux esophagitis in rats. Dig Dis Sci. 2005;50(Suppl 1):S97–S103.CrossRefPubMedGoogle Scholar
  26. 26.
    Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology. 1996;111:85–92.CrossRefPubMedGoogle Scholar
  27. 27.
    Carlsson R, Dent J, Bolling-Sternevald E, et al. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol. 1998;33:1023–1029.CrossRefPubMedGoogle Scholar
  28. 28.
    Revicki DA, Wood M, Wiklund I, Crawley J. Reliability and validity of the gastrointestinal symptom rating scale in patients with gastroesophageal reflux disease. Qual Life Res. 1998;7:75–83.CrossRefPubMedGoogle Scholar
  29. 29.
    Naito Y, Yoshikawa T, Iinuma S, et al. Local gastric and serum concentrations of rebamipide following oral administration to patients with chronic gastritis. Arzneimittelforschung. 1996;46:698–700.PubMedGoogle Scholar
  30. 30.
    Mukaida N, Shiroo M, Matsushima K. Genomic structure of the human monocyte-derived neutrophil chemotactic factor IL-8. J Immunol. 1989;143:1366–1371.PubMedGoogle Scholar
  31. 31.
    Robinson M, Lanza F, Avner D, Haber M. Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1996;124:859–867.PubMedGoogle Scholar
  32. 32.
    Baldi F, Morselli-Labate AM, Cappiello R, Ghersi S. Italian lansoprazole study group. Daily low-dose versus alternate day full-dose lansoprazole in the maintenance treatment of reflux esophagitis. Am J Gastroenterol. 2002;97:1357–1364.CrossRefPubMedGoogle Scholar
  33. 33.
    Fass R. Epidemiology and pathophysiology of symptomatic gastroesophageal reflux disease. Am J Gastroenterol. 2003;98(3 Suppl):S2–S7.CrossRefPubMedGoogle Scholar
  34. 34.
    Martinez SD, Malagon IB, Garewal HS, Cui H, Fass R. Non-erosive reflux disease (NERD)—acid reflux and symptom patterns. Aliment Pharmacol Ther. 2003;17:537–545.CrossRefPubMedGoogle Scholar
  35. 35.
    Yoshida N. Inflammation and oxidative stress in gastroesophageal reflux disease. J Clin Biochem Nutr. 2007;40:13–23.CrossRefPubMedGoogle Scholar
  36. 36.
    Isomoto H, Saenko VA, Kanazawa Y, et al. Enhanced expression of interleukin-8 and activation of nuclear factor kappa-B in endoscopy-negative gastroesophageal reflux disease. Am J Gastroenterol. 2004;99:589–597.CrossRefPubMedGoogle Scholar
  37. 37.
    Cunha FQ, Lorenzetti BB, Poole S, Ferreira SH. Interleukin-8 as a mediator of sympathetic pain. Br J Pharmacol. 1991;104:765–767.PubMedGoogle Scholar
  38. 38.
    Watkins LR, Maier SF, Goehler LE. Immune activation: the role of pro-inflammatory cytokines in inflammation, illness responses and pathological pain states. Pain. 1995;63:289–302.CrossRefPubMedGoogle Scholar
  39. 39.
    Summer GJ, Romero-Sandoval EA, Bogen O, Dina OA, Khasar SG, Levine JD. Proinflammatory cytokines mediating burn-injury pain. Pain. 2008;135:98–107.CrossRefPubMedGoogle Scholar
  40. 40.
    Wetscher GJ, Hinder RA, Bagchi D, et al. Reflux esophagitis in humans is mediated by oxygen-derived free radicals. Am J Surg. 1995;170:552–556.CrossRefPubMedGoogle Scholar
  41. 41.
    Olyaee M, Sontag S, Salman W, et al. Mucosal reactive oxygen species production in oesophagitis and Barrett’s oesophagus. Gut. 1995;37:168–173.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Norimasa Yoshida
    • 1
    • 2
  • Kazuhiro Kamada
    • 1
  • Naoya Tomatsuri
    • 1
  • Takahiro Suzuki
    • 1
  • Tomohisa Takagi
    • 2
  • Hiroshi Ichikawa
    • 2
  • Toshikazu Yoshikawa
    • 2
  1. 1.GastroenterologyJapanese Red Cross Kyoto Daiichi HospitalKyotoJapan
  2. 2.Molecular Gastroenterology and Hepatology, Graduate School of Medical ScienceKyoto Prefectural University of MedicineKyotoJapan

Personalised recommendations